SG11202107050RA - Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation - Google Patents

Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation

Info

Publication number
SG11202107050RA
SG11202107050RA SG11202107050RA SG11202107050RA SG11202107050RA SG 11202107050R A SG11202107050R A SG 11202107050RA SG 11202107050R A SG11202107050R A SG 11202107050RA SG 11202107050R A SG11202107050R A SG 11202107050RA SG 11202107050R A SG11202107050R A SG 11202107050RA
Authority
SG
Singapore
Prior art keywords
iron
subjects
risk
management
adverse events
Prior art date
Application number
SG11202107050RA
Inventor
Claes Christian Strom
Tobias Sidelmann Christensen
Thomas Goldin Diness
Lars Lykke Thomsen
Darlington Okonko
Original Assignee
Pharmacosmos Holding As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1900371.4A external-priority patent/GB201900371D0/en
Application filed by Pharmacosmos Holding As filed Critical Pharmacosmos Holding As
Publication of SG11202107050RA publication Critical patent/SG11202107050RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202107050RA 2019-01-10 2020-02-10 Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation SG11202107050RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1900371.4A GB201900371D0 (en) 2019-01-10 2019-01-10 Iron in a trial fibrillation
US201962803455P 2019-02-09 2019-02-09
EP19179820 2019-06-12
PCT/IB2020/051033 WO2020144667A1 (en) 2019-01-10 2020-02-10 Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation

Publications (1)

Publication Number Publication Date
SG11202107050RA true SG11202107050RA (en) 2021-07-29

Family

ID=71520720

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107050RA SG11202107050RA (en) 2019-01-10 2020-02-10 Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation

Country Status (7)

Country Link
US (1) US20220062331A1 (en)
EP (1) EP3908289A1 (en)
AU (1) AU2020206021A1 (en)
CA (1) CA3125413A1 (en)
GB (1) GB2595135B (en)
SG (1) SG11202107050RA (en)
WO (1) WO2020144667A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022323733A1 (en) * 2021-08-03 2024-02-29 Pharmacosmos Holding A/S Iron complex compounds for subcutaneous use in therapy of iron deficiency in companion animals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2756580A1 (en) * 2009-03-25 2010-09-30 Hans Andreasen A stable iron oligosaccharide compound
EP2537866A1 (en) 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
EP2822574A4 (en) 2012-03-05 2016-01-27 Luitpold Pharm Inc Methods for modulation of phosphorus and fgf23
KR20200044030A (en) 2017-09-11 2020-04-28 파르마코스모스 홀딩 에이/에스 Therapeutic iron complex

Also Published As

Publication number Publication date
GB2595135A (en) 2021-11-17
AU2020206021A1 (en) 2021-07-22
US20220062331A1 (en) 2022-03-03
GB2595135B (en) 2022-10-26
EP3908289A1 (en) 2021-11-17
CA3125413A1 (en) 2020-07-16
WO2020144667A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
IL292821A (en) Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
ZA202007993B (en) Methods of reducing the risk of cardiovascular events in a subject
SG11202104158SA (en) Composition and method for treating the lungs
EP3579827A4 (en) Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
IL282375A (en) 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating α-synucleinopathies, tauopathies, and other disorders
GB2595135B (en) Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation
SG11202112515RA (en) Methods and compositions for treating liver disorders
EP3891274C0 (en) Compositions and methods for treating ornithine transcarbamylase deficiency
SG11202012426WA (en) Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
IL304736A (en) Binding agents and methods of using the same
EP3541185C0 (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
IL288843A (en) Treating iron deficiency in subjects at risk of cardiovascular adverse events
ZA202007183B (en) Compositions and methods for treating the eye
SG11202111509PA (en) Methods of assessing and treating hepatic encephalopathy
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
EP3781262A4 (en) Compositions and methods for treating cardiovascular disease in selected patients
ZA202107513B (en) Compounds and compositions comprising the same for treating hypertension or heart failure
IL287955A (en) Use of co-crystals of tramadol and celecoxib for treating pain while reducing the abuse liability of tramadol
EP3496742A4 (en) Peptibodies, compositions thereof, and methods of treating atrial fibrillation
ZA202108822B (en) System and process for determining in-line the characteristics of spent balls and pieces of same
IL281501A (en) Compositions and methods for treating cellulite
EP3691635A4 (en) Methods and compositions involving bucindolol for the treatment of atrial fibrillation
EP3421025A4 (en) Method for treating and preventing peripheral circulation disorders and inversion table for the implementation thereof
IL312523A (en) Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism
GB201903259D0 (en) Systems and methods for treating cardiac arrhythmia